PMID- 37578746
OWN - NLM
STAT- MEDLINE
DCOM- 20230914
LR  - 20230922
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 34
IP  - 9
DP  - 2023 Oct 1
TI  - Meta-analysis of proton pump inhibitor use and the risk of developing gastric 
      cancer or colorectal cancer.
PG  - 971-978
LID - 10.1097/CAD.0000000000001418 [doi]
AB  - To evaluate the relationship between the use of proton pump inhibitors (PPI) and 
      the risk of gastric cancer and colorectal cancer by using meta-analysis. Computer 
      search PUBMED, EMBASE, Cochrane Library, CNKI and Wanfang database to obtain 
      relevant literature on the use of PPI and the risk of gastric cancer and 
      colorectal cancer, extract relevant data, and use Stata14.0 for Meta-analysis. A 
      total of 24 articles were included, including 12 articles for gastric cancer and 
      12 articles for colorectal cancer. A total of 5 313 749 persons were included in 
      the study and analysis. Meta-analysis results showed that the risk of gastric 
      cancer in PPI users was significantly increased [risk ratio (RR) = 2.04, 95% 
      confidence interval (CI) (1.33-2.75)], and the regional subgroup analysis results 
      showed that in Europe [RR = 2.01, 95% CI (0.92, 3.09), P < 0.05] and Asia 
      [RR = 2.15, 95% CI (1.16, 3.14), P < 0.05] This risk is higher, and Asia is 
      higher than Europe. The risk of colorectal cancer is slightly increased [RR = 1. 
      22, 95% CI (1.03, 1.40, P < 0.05], and the regional subgroup analysis results 
      show that in Europe [RR = 1.05 95% CI (0.98, 1.12), P < 0.05] and Asia 
      [RR = 1.18, 95% CI (1.10, 1.27), P < 0.05]. This risk is low, but Asia is higher 
      than Europe. The use of PPI significantly increases gastric cancer However, the 
      risk of colorectal cancer is not significantly increased. The risk of gastric 
      cancer and colorectal cancer in the population using PPI in Asia is higher than 
      that in Europe.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Liu, Ke
AU  - Liu K
AD  - Department of Gastrointestinal Surgery, People's Hospital of Leshan.
AD  - Department of Nursing, People's Hospital of Leshan, Sichuan, China.
FAU - Wang, Yong-Hong
AU  - Wang YH
AD  - Department of Gastrointestinal Surgery, People's Hospital of Leshan.
FAU - Wang, Jun
AU  - Wang J
AD  - Department of Nursing, People's Hospital of Leshan, Sichuan, China.
FAU - Chen, Bing
AU  - Chen B
AD  - Department of Nursing, People's Hospital of Leshan, Sichuan, China.
FAU - Luo, Na
AU  - Luo N
AD  - Department of Nursing, People's Hospital of Leshan, Sichuan, China.
FAU - Gong, Juan
AU  - Gong J
AD  - Department of Nursing, People's Hospital of Leshan, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230815
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - Proton Pump Inhibitors/adverse effects
MH  - *Stomach Neoplasms/chemically induced/epidemiology
MH  - *Colorectal Neoplasms/chemically induced/epidemiology
EDAT- 2023/08/14 12:43
MHDA- 2023/09/14 06:42
CRDT- 2023/08/14 11:33
PHST- 2023/09/14 06:42 [medline]
PHST- 2023/08/14 12:43 [pubmed]
PHST- 2023/08/14 11:33 [entrez]
AID - 00001813-990000000-00204 [pii]
AID - 10.1097/CAD.0000000000001418 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2023 Oct 1;34(9):971-978. doi: 10.1097/CAD.0000000000001418. 
      Epub 2023 Aug 15.